Explore the Agenda
8:00 am Check In & Light Refreshments
Workshop A
9:00 am Identifying the Indications & Disease Stages Most Likely to Benefit from Complement-Based Therapies to Expand Scope of Treatment
Whilst complement dysregulation is observed across a broad range of diseases, it remains unclear where complement therapeutics can deliver maximum benefit to patients whilst maintaining healthy immune function.
This workshop will cover:
- Evaluating which indications offer the greatest opportunity for complement intervention and determining where complement biology is most likely to translate into meaningful patient benefit
- Debating the role of complement therapies in acute versus chronic disease settings and identifying how dosing strategies and endpoints may differ between the two
- Exploring the potential for complement therapeutics beyond orphan diseases, including how to position complement modulation within complex, multifactorial conditions where complement is not the primary disease driver, as well as the potential of complement in oncology
- Assessing when complement intervention should occur within the patient journey, including optimal treatment windows, sustainable dosing regimens and approaches to maximizing long-term therapeutic impact
12:00 pm Lunch Break & Networking
Workshop B
1:00 pm Identifying Novel Complement Targets & Accurately Measuring Target Engagement to Guide Therapeutic Design, Facilitate Differentiation & Improve Clinical Outcomes
As the complement field expands beyond established targets, the challenge is identifying the mechanisms most likely to drive meaningful clinical benefit and developing robust approaches to demonstrate target engagement, differentiate therapeutic strategies and inform clinical development.
This workshop will cover:
- Evaluating emerging targets beyond C3 and C5, including upstream regulators, alternative pathway components, membrane attack complex targets and intracellular complement
- Elucidating pathological mechanisms to guide target selection and maximize therapeutic efficacy while preserving immune function
- Applying proteomics, biomarkers and functional assays to quantify complement activity, identify novel disease-driving mechanisms and de-risk target selection
- Addressing challenges in measuring target engagement, including sample acquisition, low-abundance proteins, pathway redundancy and the need for clinically meaningful biomarkers that accurately reflect biological activity
- Addressing challenges in sample collection to measure target engagement across a complex complement cascade